Skip to Main Content

A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD)

Conditions

Diseases of the Nervous System | Mental Health & Behavioral Research | Alzheimer's Disease

Phase III

What is the purpose of this trial?

Brief Summary:

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.

Alzheimer’s Disease Research Unit (ADRU) -  http://www.alzheimers.yale.edu



  • Trial with
    Eisai Pharmaceuticals
  • Start Date
    10/22/2019
  • End Date
    03/06/2024
Trial Image

For more information about this study, contact:

Victoria Kominek

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/25/2019
  • Study HIC
    #2000026162